Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In a crisis, creating DNA vaccine could help save lives, slow spread of ’bird flu’

19.10.2005


Researchers scrambling to combat a virulent form of bird flu that could mutate into a form easily spread among humans should consider developing vaccines based on DNA, according to British biochemical engineers. DNA vaccines, they say, can be produced more rapidly than conventional vaccines and could possibly save thousands of lives if a global influenza outbreak occurs.



A DNA-based vaccine could be a potent weapon against this emerging threat, particularly if enough conventional vaccine isn’t available, according to Peter Dunnill, DSc., and his colleagues at University College London. However, they caution that any DNA vaccine should only be used as needed to slow the spread of the disease because the technique is largely untested in humans. The analysis appears in the November-December issue of the journal Biotechnology Progress, a co-publication of the American Chemical Society and the American Institutes of Chemical Engineers.

The avian virus, H5N1, has spread among birds throughout Southeast Asia and has been recently detected in Eastern Europe. The virus has killed more than 60 people in Asia since 2003 and forced the slaughter of millions of birds. There are no confirmed cases of human-to-human transmission of this flu, but that could change as the virus continues to mutate, Dunnill says.


If that occurs, current production facilities are unlikely to meet global demands for conventional vaccines in time to avert a pandemic, Dunnill says. But it might be possible to quickly produce a DNA vaccine by adapting the manufacturing processes of selected biopharmaceutical and antibiotic plants in countries such as the United States, China and India.

"A DNA vaccine is not a panacea, however it could be useful if the situation gets out of hand," Dunnill says. "But if we’re going to try it, we need to move. You can’t expect to walk into a production facility, hand over the instructions, and expect them to make it on the spot. It’s going to take some weeks, and we really don’t know how much time we have."

A DNA vaccine could be produced in as little as two or three weeks, Dunnill says. To do it, scientists would create a "loop" of DNA that contains the construction plans for a protein on the outer surface of the H5N1 virus. When that DNA is injected into cells, it would quickly reproduce the protein and trigger immunization in much the same way as a conventional vaccine.

In contrast, producing conventional vaccines from viruses incubated in fertilized eggs can take up to six months, which is too long to effectively prevent an influenza pandemic, Dunnill says.

Although no commercial influenza DNA vaccine is currently available, these vaccines have worked well in animals. However, human trials are still in the early stages so the safety and efficacy of these vaccines isn’t fully established in people. But these trials could be accelerated, Dunnill says, particularly if the H5N1virus eventually causes large numbers of human deaths and out paces the supply of conventional vaccine. In the worst case scenario, he suggests, using a DNA vaccine could be a "stop-gap" measure until enough conventional vaccine is available to corral the pandemic.

Michael Bernstein | EurekAlert!
Further information:
http://www.acs.org

More articles from Life Sciences:

nachricht Rochester scientists discover gene controlling genetic recombination rates
23.04.2018 | University of Rochester

nachricht One step closer to reality
20.04.2018 | Max-Planck-Institut für Entwicklungsbiologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Structured light and nanomaterials open new ways to tailor light at the nanoscale

23.04.2018 | Physics and Astronomy

On the shape of the 'petal' for the dissipation curve

23.04.2018 | Physics and Astronomy

Clean and Efficient – Fraunhofer ISE Presents Hydrogen Technologies at the HANNOVER MESSE 2018

23.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>